NCT02165111View on ClinicalTrials.gov

Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome

PHASE3CompletedINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions

SclerodermaRaynaud's Syndrome

Interventions

DRUG

Onabotulinumtoxin A

DRUG

sterile saline solution

Trial Locations (1)

21224

Johns Hopkins Bayview Medical Center, Baltimore

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Allergan

INDUSTRY

lead

Johns Hopkins University

OTHER